No abstract

bone mineral density (table 2). Factors associated with low bone mineral density in a univariate logistic regression analysis were: the use of mycophenolate mofetil (p=0.021) and the presence of LN (p=0.007), while LN also associated with low bone density (p= 0.008) in a multivariate analysis. The skin involvement was the most common clinical manifestation in both JSLE patient groups. The treatment was more aggressive in patients with LN, including the use of cyclophosphamide, mycophenolate and rituximab, but there was no difference regarding the length of the steroid treatment (table 3). The majority of the patients (67%) had one flare of nephritis and the number of flares ranged from 2 (13%) to 12 (2.2%) for the rest of the patients in this cohort with disease duration ranging from 8-12 years. The class of nephritis was reported in 34 out of 45 patients, and focal lupus nephritis (class III) was the most common type (44%). There were no statistical significant differences in the baseline characteristics or treatments among the different classes of LN. Conclusion Low bone mineral density is common in patients with JSLE 3 , but this is the first study highlighting the association of low bone density with LN and the lack of association with the total duration of steroid treatment or other clinical manifestations.

transglutaminase (IgA) antibodies. Six patients were DQ2 positive. After being diagnosed of CD and starting the GFD, SLE patients seem to improve especially the leukopenia, lymphopenia and oral aphtosis, as well as SLEDAI score (showed in attached graphics). Conclusions SLE patients with CD diagnosis and who started a GFD, showed improvement of leukopenia, lymphopenia, oral aphtosis and even SLEDAI. In SLE patients with recurrent oral aphtosis and/or gastrointestinal unspecific symptoms, CD should be considered, but since serological screening displays a low sensitivity, HLA testing could be helpful. Gastroscopy should be considered, with biopsy and flow cytometer in uncertain cases. Even though, further studies, especially looking for different clinical profiles and longer observational period are needed.

No abstract

Background Neuropsychiatric manifestations in patients with systemic lupus erythematosus (SLE), termed neuropsychiatric SLE (NPSLE), involve a wide variety of neurological and psychiatric manifestations with a complex approach. The aim of this study was to determine the prevalence of mental disorders and neuropsychiatric involvement in a group of patients with SLE and to examine the relationship with other clinical manifestations. Methods A single center, retrospective, case control study was including patients 18 years and older diagnosed with SLE in a tertiary hospital. Clinical and demographical variables were collected. NPSLE was defined by classification criteria, and others minor nonspecific NPSLE manifestations (depression, anxiety, dizziness) were collected. Statistical analysis was carried out using R software. Results From a total of 66 patients 24.2% (16 patients) had at least one mental disorder or neuropsychiatric manifestation. The most frequently reported was depression (n=7, 43.8%), dizziness (n=5; 31,2%); headache (n=4; 25%); insomnia (n=2; 12.5%) and cognitive impairment (n=2; 12.5%). Brain MRI nonspecific findings were reported in 2 patients (12.5%). ANA was positive in all cases. The prevalence of anti-Rib-P was very low, only present in one patient (1.5%). 8 patients (12.1%) had secondary antiphospholipid syndrome (APS). Associations with APS, other manifestations or corticosteroid use were not statistically significant. Conclusions There is a low prevalence of severe neuropsychiatric syndromes in our cohort. Almost 1/4 of our cohort had Abstract P146 Table 1 Characteristics of the population studied and comparison between patients with and without fragility fractures